Of the 1043 patients, 62.51% were men, and their mean age was 65.82±12.79 years. Mean values were 62.45±19.61 U/L for ALP and 1.07±0.21 mmol/L for phosphate. Clinical characteristics and their associations with ALP/phosphate are Background and Purpose-Higher serum alkaline phosphatase (ALP) and phosphate levels are associated with atherosclerotic disease and an increased risk of cardiovascular events. However, the association of ALP/phosphate with cerebral atherosclerosis and prognosis in patients with acute stroke is not well known. Methods-In 1034 patients with first-ever acute cerebral infarction, levels of ALP and phosphate were compared with (1) cerebral atherosclerosis and (2) poor long-term functional outcomes as defined by the modified Rankin Scale >2 at 3 months after stroke onset. Results-ALP levels were not associated with cerebral atherosclerosis. However, higher levels of ALP were associated with a poor functional outcome (adjusted odds ratio per 1 SD, 1.25; 95% confidence interval, 1.04-1.50). Phosphate was associated with neither cerebral atherosclerosis nor functional outcome. Conclusions-A higher level of ALP was not associated with cerebral atherosclerosis but was an independent prognostic factor for long-term functional outcome after acute cerebral infarction. shown in Tables I and II in the online-only Data Supplement. ALP was associated with old age, higher frequency of hypercholesterolemia, and higher hemoglobin, cholesterol, alanine aminotransferase, and glucose. Phosphate was associated with female sex, lower National Institutes of Health Stroke Scale score at admission, higher cholesterol, triglyceride, and calcium, and lower hemoglobin and high-sensitivity C-reactive protein.
S erum levels of alkaline phosphatase (ALP) and phosphate are primarily used as markers of liver disease or bone disease in clinical practice. Recent epidemiological studies have demonstrated that elevated ALP or phosphate levels are associated with the presence of atherosclerosis in coronary and peripheral arteries, increased cardiovascular events, and mortality. [1] [2] [3] [4] [5] ALP and phosphate are also considered to be surrogate markers of systemic inflammation, malnutrition, and metabolic syndrome, which may lead to worse clinical outcomes in patients with stroke.
1,3 Therefore, we investigated whether ALP/phosphate is associated with cerebral atherosclerosis and long-term functional outcomes in patients with acute cerebral infarction.
Methods
This was a hospital-based, retrospective observational study. Candidates were patients admitted with a first-ever acute cerebral infarction. Patient inclusion and exclusion criteria are shown in Figure I in the online-only Data Supplement. Serum ALP and phosphate levels were measured at admission using peripheral venous blood with a Hitachi 7600-210 automatic analyzer (HITACHI, Tokyo, Japan). We collected data, including baseline characteristics, National Institutes of Health Stroke Scale score at admission, risk factors, and laboratory findings.
Cerebral atherosclerosis was defined as occlusion or significant stenosis (≥50%) of cerebral artery on the basis of digital subtraction angiography, magnetic resonance angiography, or computed tomographic angiography. The presence of cerebral atherosclerosis was assessed in intracranial cerebral arteries (anterior cerebral, middle cerebral, posterior cerebral, basilar, intracranial internal carotid, and intracranial vertebral arteries) and extracranial cerebral arteries (extracranial internal carotid and extracranial vertebral arteries). Then, patients were subdivided into 4 groups according to the location of cerebral atherosclerosis (no atherosclerosis, only intracranial, only extracranial, and both intracranial and extracranial atherosclerosis). We also collected data for the presence of coronary artery disease and peripheral artery disease. We defined a poor functional outcome as a modified Rankin Scale score of >2 at 3 months after stroke onset. Definition of risk factors, collected data, and statistical methods is shown in the Methods in the online-only Data Supplement. The Institutional Review Board of Severance Hospital, Yonsei University Health System, approved this study and waived the need for informed consent because of the retrospective and observational nature of the study.
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shown in Tables I and II in the online-only Data Supplement. ALP was associated with old age, higher frequency of hypercholesterolemia, and higher hemoglobin, cholesterol, alanine aminotransferase, and glucose. Phosphate was associated with female sex, lower National Institutes of Health Stroke Scale score at admission, higher cholesterol, triglyceride, and calcium, and lower hemoglobin and high-sensitivity C-reactive protein.
There were 623 patients (59.73%) with cerebral atherosclerosis. The levels of ALP/phosphate were not associated with intracranial or extracranial cerebral atherosclerosis (Table 1) . When we subdivided patients according to the degree of cerebral atherosclerosis (no atherosclerosis, <50%, 50%-75%, and ≥75% or occlusion), there was no significant difference of ALP/phosphate among them (Table III in Table 2 ). Penalized-spline curve demonstrated a positive relationship between levels of ALP and an increased risk for poor functional outcomes (Figure) .
Discussion
In this study, we tested the hypothesis that elevated ALP/ phosphate levels are associated with cerebral atherosclerosis, which was based on previous reports that showed a higher prevalence of coronary artery disease and peripheral artery disease in patients with elevated ALP/phosphate levels. However, such a relationship between serum ALP/phosphate levels and cerebral atherosclerosis was not found in our study. The action of ALP/phosphate might differ in each vascular bed. Susceptibility to atherosclerosis is strongly influenced by intrinsic differences in the cells composing each vascular system. 6 Associated risk factors and pathological findings, including calcification, differ according to the location of the atherosclerosis. Although we defined atherosclerosis as significant stenosis (≥ 50%) on angiographic studies, most previous studies used definitions based on coronary artery calcium score, ankle-brachial index, and carotid intima thickness. ALP and phosphate are suggested to enhance medial calcification and stiffening of the vessel and further atherosclerosis. 5, 7 Medial calcification has a longitudinal, uniform distribution (pipeline-like) without focal luminal narrowing. 6 Thus, ALP-/ phosphate-related medial calcification and atherosclerosis might be undetected in angiographic studies.
Inflammation may be a link between elevated ALP levels and poor clinical outcomes. 3, 4 ALP is increased in inflammatory conditions, poor nutrition, and infections, which could lead to worse functional outcomes after stroke. 3, 8 In contrast to ALP, phosphate is not associated with functional outcomes in this study. Although there are reports for increased mortality with high levels of serum phosphate, low levels of phosphate are also associated with malnutrition, low physical activity, hypertension, and metabolic syndrome. 3, 9 Racial differences and genetic polymorphisms among Western and Asian individuals might be present. 5 Compared with Asian diets, Western diets are relatively high in bioavailable phosphate. 5 The lack of an association in this study between phosphate and functional outcomes in Asian patients with stroke may be partly ascribed to the complex nature of phosphate.
This study has some limitations. Selection bias might be present because this was a retrospective observational study in a single center, and many patients were excluded because of missing data. The mechanism behind the association between 
Conclusions
We did not find a significant association between serum ALP/phosphate and cerebral atherosclerosis. Patients with elevated ALP levels had poor functional outcomes after acute cerebral infarction. 
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Collection of clinical data
We collected clinical data including sex, age, time from stroke onset to hospital arrival, and National Institute of Health Stroke Scale (NIHSS) score at admission. Data for the presence of hypertension, diabetes mellitus, hypercholesterolemia, current smoking, atrial fibrillation, coronary artery disease (CAD), peripheral artery disease (PAD), and use of thrombolysis (intravenous, intra-arterial or combined) were obtained. We collected other laboratory results that might act as confounders, including total white blood cell count, hemoglobin, highsensitivity C-reactive protein, total cholesterol, triglyceride, albumin, total bilirubin, aspartate aminotransferase, alanine aminotransferase, calcium, glucose, and estimated glomerular filtration rate (eGFR 
Definition of risk factors
Hypertension was diagnosed when a patient was on anti-hypertensive medication or had systolic blood pressures ≥ 140 mmHg or diastolic blood pressures ≥ 90 mmHg on repeated measurements during admission. Diabetes mellitus was diagnosed if the patient had a fasting plasma glucose level ≥ 7.0 mmol/L or was being treated with anti-diabetic medications or insulin. Hypercholesterolemia was diagnosed if the patient had low-density lipoprotein cholesterol ≥ 4.1 mmol/L, total cholesterol ≥ 6.2 mmol/L, or the patient was treated with lipid lowering agents after diagnosis of hypercholesterolemia. Current smoking was defined as having smoked a cigarette in the year prior to admission. The presence of CAD was identified when a patient had a history of acute myocardial infarction, unstable angina, angiographically confirmed coronary artery occlusive disease, or a coronary artery bypass graft or percutaneous coronary artery stent/angioplasty. The presence of PAD was determined if a patient had an ankle-brachial index < 0.9 on either the right or left side measured during admission, or a previous history of angiographically-confirmed PAD.
Assessment for cerebral atherosclerosis
MRA was conducted using a 3.0-T system (Achieva, Philips, Best, the Netherlands, or Trio, Siemens, Erlangen, Germany). CTA was performed using a 64-slice CT scanner (Siemens Sensation 64, Siemens Medical Solutions, Forchheim, Germany). For those patients who received both DSA and MRA or CTA, the results of the DSA were used for analysis. The degree of stenosis in the extracranial cerebral artery was measured using the method in the North American Symptomatic Carotid Endarterectomy Trial, 2 and that in the intracranial cerebral artery was measured using the method in the Warfarin vs. Aspirin for Symptomatic Intracranial Disease Trial. 3 All angiographic findings were evaluated and determined during the weekly stroke conference based on the consensus of stroke specialists and on the radiology report, and were prospectively registered in the Yonsei stroke registry.
Patient management and determination of functional outcome
Patients were treated with the standard stroke treatment protocols of our hospital, which are based on the guidelines for ischemic stroke. 5, 6 Patients admitted within 6 hours of stroke onset were considered for intravenous tissue-type plasminogen activator, intra-arterial thrombolysis, or combined thrombolysis. 7 Patients with high-risk potential cardioembolic sources such as atrial fibrillation, intracardiac thrombus, or a mechanical prosthetic valve received an oral anticoagulant. Others received antiplatelet agents unless the patient had a contraindication to antithrombotic medication. All patients except those with contraindications were given a statin. Early rehabilitation was strongly encouraged in patients with neurological deficits. Long-term functional outcome was assessed using the modified Rankin Scale (mRS) via a direct interview performed by a clinician or a telephone interview conducted by a well-trained research nurse.
Statistical analyses
All statistical analyses were performed using the R package for Windows (version 3.0. To evaluate the association between clinical characteristics and ALP/phosphate, patients were subdivided into quartile groups according to the levels of ALP and phosphate. The difference across the quartile groups were evaluated using Fisher's exact test, one-way analysis of variance or the Kruskal-Wallis test, appropriately. In subgroups of patients, levels of ALP/phosphate were compared using independent t-test or one-way analysis of variance.
Univariate logistic regression was performed to identify potential variables associated with a poor functional outcome (mRS >2). The levels of ALP and phosphate were treated as continuous variables in the regression analysis. If there was a significant association between ALP/phosphate and a poor functional outcome, we performed multivariate logistic regression adjusted for sex, age, and those variables which had p<0.05 in univariate analysis.
Additionally, penalized regression smoothing splines (P-spline) were performed to exam dose-response relation and to illustrate the likelihood of poor functional outcome across the levels of ALP/phosphate. The P-spline curve was fitted via the "gam" function in the "mgcv" package of R software. All statistical tests were two-tailed, and p<0.05 was considered statistically significant.
Supplementary Figure I.
Flowchart of patient inclusion and exclusion criteria. mRS indicates modified Rankin Scale. Values are mean ± standard deviation. P-value is derived from one-way analysis of variance test. .001 OR and P-value are derived from univariate logistic regression using modified Rankin Scale >2 as the dependent variable. NIHSS indicates National Institute of Health Stroke Scale; hs-CRP, high-sensitivity Creactive protein; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence intervals.
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